$26.850
+0.615 (+2.29%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
Loading chart…
該買進 Apnimed Inc 股票嗎？
Apnimed, Inc. is a good buy right now due to its strong recent performance, with a year-to-date change of +85.69% and a positive analyst outlook, including a target price of $60 from Cantor Fitzgerald. The upcoming FDA decision for its lead product, Oxnimbi, on February 28, 2027, adds a significant potential catalyst for growth. However, the main risk is the regulatory scrutiny associated with the FDA approval process, which could impact the stock negatively.
APMD 股價於 Tuesday 收在 $26.85，此前上漲 +2.29%
Apnimed Inc (APMD) last closed at $26.85, gaining +2.29%. These facts feed the 1-day and 1-week APMD price prediction above.
預測驅動因素
Apnimed Inc（APMD）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Seasonality
Positive
Bullish
APMD 季節性分析
Loading chart…
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。